MHP 133
目录号 : GC30446MHP133是一种多靶点抑制剂,可以抑制AChE的活性,KKi值为69μM;同时抑制毒蕈碱M1和M2受体,5HT4受体和咪唑I2受体。
Cas No.:147340-43-0
Sample solution is provided at 25 µL, 10mM.
a drug with multiple CNS targets, and inhibits acetylcholinesterase (AChE) with Ki of 69 μM; also active against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors.
MHP-133 is be active (>50% displacement or activity) against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors. MHP-133 exhibits this nicotinic-like activity in the cell line. Although the ED50 for inducing TrkA expression is only about 1 μM, it does predicts the cytoprotective action of MHP-133 in differentiated PC-12 cells deprived of growth factor for 24 h. MHP-133 (10-100 μM) significantly increases the levels of sAPP from cultured astrocytes by 40-60%. MHP-133 produces a bi-phasic effect on slice survival, particularly in the dentate gyrus and the CA1 regions[1].
In rats, MHP-133 (50, 100, or 200 μg/kg, i.p.) enhances acquisition of the task and increases task accuracy. MHP-133 elicits significant improvements in task accuracies during sessions initiated 10 min after dosing[1].
[1]. Buccafusco JJ, et al. MHP-133, a drug with multiple CNS targets: potential for neuroprotection and enhanced cognition. Neurochem Res. 2007 Jul;32(7):1224-37. Epub 2007 Apr 3.
Kinase experiment: | Rat cerebral cortex is homogenized in ice cold 50 mM Tris-HCl buffer containing 120 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 2 mM CaCl2 (pH 7.0). The homogenate is centrifuged at 37,200 g for 20 min at 0°C. The pellet is washed twice and resuspended in fresh buffer. For nicotinic receptor binding, [3H]cytisine is incubated with 0.5 mg protein and various concentrations of MHP-133 or other ligand in a final volume of 250 μL ta 4°C for 120 min. About 10 μM (-)-nicotine is used to determine nonspecific binding. Bound radioactivity is isolated by rapid filtration through polyethyleneimine-treated glass fiber filters and by washing several times with icecold buffer (Tris-HCl, 50 mM). Filters are soaked in scintillation fluor for 6 h prior to quantification or radioactivity in a scintillation counter. Data are presented in triplicate. |
Cell experiment: | PC-12 cells are maintained in 150-cm2 tissue-culture flasks in Dulbecco's modified Eagles medium containing 7% horse serum, 7% fetal calf serum, 1% nonessential amino-acids and 1% streptomycin (DMEM). The cells are incubated at 37°C in a 5% CO2-enriched, humidified atmosphere. For the actual experiments PC-12 cells are plated on poly-L-lysine coated 24-well plates at a density of 40,000 cells per well in DMEM medium containing 50 ng/mL nerve growth factor (NGF). To attain maximum differentiation, the cells are maintained in DMEM.NGF medium for 7 days with the medium being changed every 2 or 3 days. Next, the differentiated cells are incubated with vehicle or with a test drug (prepared in serum-free DMEM media with no exogenous NGF) for 24 h. A parallel set of control cells are maintained in DMEM.NGF medium in each experiment. Cell viability (cytotoxicity) is determined by using the Cell Titer 96 cell proliferation/cytotoxicity assay kit, which is based on the cellular conversion of a 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenltetrazolium bromide (MTT) into a formazan product that can be detected spectrophotometrically. At the completion of the incubation period, the culture medium is aspirated and 15 μL of dye solution in DMEM is added. After 4 h at 37°C, 100 μL of solubilization/stop solution is added and the absorbance of solubilized MTT formazan products is measured at 579 nm. All data are normalized to untreated control cells in each plate. |
Animal experiment: | Male Sprague-Dawley, outbred Wistar rats weighing 250-300 g are housed separately in our animal care facility for 1 week prior to experimentation. At the time of the experiment the 40 animals are randomLy assigned to one of four treatment groups, a saline vehicle group, or a group to be administered 50, 100 or 200 μg/kg of MHP-133. Vehicle (1 mL/kg body weight) is administered i.p. 30 min prior to testing in the Morris Water Maze apparatus. The apparatus consists of a water-filled (room temperature) tub 1.2 m in diameter. A mounting platform is fixed in place and slightly submerged in the northwest quadrant of the tub. The platform is similar in color to the inner surface of the tub so as to make it difficult to visualize. The tub is always maintained in the same orientation with respect to visual cues placed on the walls, around the testing room. Rats are tested by placing the animal in the water facing away from the platform. Four consecutive trials are administered with 10 min between trials. In each successive trial the rats are placed first in the south quadrant of the tub, followed by the north, east and west quadrants. The time required for the rat to find (place at least 2 paws on) the platform is monitored to the nearest 0.1 s. All rats found the platform in less than 90 s. |
References: [1]. Buccafusco JJ, et al. MHP-133, a drug with multiple CNS targets: potential for neuroprotection and enhanced cognition. Neurochem Res. 2007 Jul;32(7):1224-37. Epub 2007 Apr 3. |
Cas No. | 147340-43-0 | SDF | |
Canonical SMILES | O=C(N/N=C/C1=C(OC(N(C)C)=O)C=CC=[N+]1C)NC2=CC=CC=C2.[Cl-] | ||
分子式 | C17H20ClN5O3 | 分子量 | 377.83 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.6467 mL | 13.2335 mL | 26.4669 mL |
5 mM | 0.5293 mL | 2.6467 mL | 5.2934 mL |
10 mM | 0.2647 mL | 1.3233 mL | 2.6467 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet